182 related articles for article (PubMed ID: 32067817)
1. Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese children: A phase IV, open-label, and randomized controlled trial.
Xu Q; Cao Q; Yang W; Liu X; Liu H; Tian X; Li J; Fang X; Jia N; Zeng G; Xu A
Vaccine; 2020 Mar; 38(12):2671-2677. PubMed ID: 32067817
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.
Hu YM; Wang X; Wang JZ; Wang L; Zhang YJ; Chang L; Liang ZL; Xia JL; Dai QG; Hu YL; Mao QY; Zhu FC; Song YF; Gao F; Chen JT
Clin Vaccine Immunol; 2013 Dec; 20(12):1805-11. PubMed ID: 24108780
[TBL] [Abstract][Full Text] [Related]
3. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
Wei M; Meng F; Wang S; Li J; Zhang Y; Mao Q; Hu Y; Liu P; Shi N; Tao H; Chu K; Wang Y; Liang Z; Li X; Zhu F
J Infect Dis; 2017 Jan; 215(1):56-63. PubMed ID: 28077584
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an inactivated enterovirus A71 vaccine in children 3-6 years and 2-35 months of age- an open-label, randomized phase IIb clinical trial.
Hung MC; Cho CY; Chen CJ; Lai CC; Wu KG
Vaccine; 2019 Sep; 37(37):5559-5566. PubMed ID: 31399275
[TBL] [Abstract][Full Text] [Related]
5. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial.
Shenyu W; Jingxin L; Zhenglun L; Xiuling L; Qunying M; Fanyue M; Hua W; Yuntao Z; Fan G; Qinghua C; Yuemei H; Xin Y; Huijie G; Fengcai Z
J Infect Dis; 2014 Oct; 210(7):1073-82. PubMed ID: 24625805
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu FC; Meng FY; Li JX; Li XL; Mao QY; Tao H; Zhang YT; Yao X; Chu K; Chen QH; Hu YM; Wu X; Liu P; Zhu LY; Gao F; Jin H; Chen YJ; Dong YY; Liang YC; Shi NM; Ge HM; Liu L; Chen SG; Ai X; Zhang ZY; Ji YG; Luo FJ; Chen XQ; Zhang Y; Zhu LW; Liang ZL; Shen XL
Lancet; 2013 Jun; 381(9882):2024-32. PubMed ID: 23726161
[TBL] [Abstract][Full Text] [Related]
7. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.
Liu L; Mo Z; Liang Z; Zhang Y; Li R; Ong KC; Wong KT; Yang E; Che Y; Wang J; Dong C; Feng M; Pu J; Wang L; Liao Y; Jiang L; Tan SH; David P; Huang T; Zhou Z; Wang X; Xia J; Guo L; Wang L; Xie Z; Cui W; Mao Q; Liang Y; Zhao H; Na R; Cui P; Shi H; Wang J; Li Q
BMC Med; 2015 Sep; 13():226. PubMed ID: 26381232
[TBL] [Abstract][Full Text] [Related]
8. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: A further observation.
Hu Y; Zeng G; Chu K; Zhang J; Han W; Zhang Y; Li J; Zhu F
Hum Vaccin Immunother; 2018 Jun; 14(6):1517-1523. PubMed ID: 29482422
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ
Lancet; 2013 Mar; 381(9871):1037-45. PubMed ID: 23352749
[TBL] [Abstract][Full Text] [Related]
10. An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages.
Tambyah PA; Oon J; Asli R; Kristanto W; Hwa SH; Vang F; Karwal L; Fuchs J; Santangelo JD; Gordon GS; Thomson C; Rao R; Dean H; Das SC; Stinchcomb DT
Vaccine; 2019 Jul; 37(31):4344-4353. PubMed ID: 31230881
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.
Zhu F; Xu W; Xia J; Liang Z; Liu Y; Zhang X; Tan X; Wang L; Mao Q; Wu J; Hu Y; Ji T; Song L; Liang Q; Zhang B; Gao Q; Li J; Wang S; Hu Y; Gu S; Zhang J; Yao G; Gu J; Wang X; Zhou Y; Chen C; Zhang M; Cao M; Wang J; Wang H; Wang N
N Engl J Med; 2014 Feb; 370(9):818-28. PubMed ID: 24571754
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial.
Zhang Z; Liang Z; Zeng J; Zhang J; He P; Su J; Zeng Y; Fan R; Zhao D; Ma W; Zeng G; Zhang Q; Zheng H
J Infect Dis; 2019 Jul; 220(3):392-399. PubMed ID: 30891604
[TBL] [Abstract][Full Text] [Related]
13. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
14. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine.
Cheng A; Fung CP; Liu CC; Lin YT; Tsai HY; Chang SC; Chou AH; Chang JY; Jiang RH; Hsieh YC; Su IJ; Chong PC; Hsieh SM
Vaccine; 2013 May; 31(20):2471-6. PubMed ID: 23541623
[TBL] [Abstract][Full Text] [Related]
15. Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints.
Zhu W; Jin P; Li JX; Zhu FC; Liu P
Expert Rev Vaccines; 2017 Sep; 16(9):945-949. PubMed ID: 28548626
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial.
Zhang L; Gao F; Zeng G; Yang H; Zhu T; Yang S; Meng X; Mao Q; Liu X
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):440-447. PubMed ID: 33269798
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan.
Huang LM; Chiu CH; Chiu NC; Lin CY; Li MT; Kuo TY; Weng YJ; Hsieh EF; Tai IC
Vaccine; 2019 Mar; 37(13):1827-1835. PubMed ID: 30803843
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial.
Li YP; Liang ZL; Xia JL; Wu JY; Wang L; Song LF; Mao QY; Wen SQ; Huang RG; Hu YS; Yao X; Miao X; Wu X; Li RC; Wang JZ; Yin WD
J Infect Dis; 2014 Jan; 209(1):46-55. PubMed ID: 23922377
[TBL] [Abstract][Full Text] [Related]
19. Progress on the research and development of inactivated EV71 whole-virus vaccines.
Liang ZL; Mao QY; Wang YP; Zhu FC; Li JX; Yao X; Gao F; Wu X; Xu M; Wang JZ
Hum Vaccin Immunother; 2013 Aug; 9(8):1701-5. PubMed ID: 23744508
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months.
Gu W; Zeng G; Hu YM; Hu YS; Zhang Y; Hu YL; Wang Y; Li JX; Zhu FC
Expert Rev Vaccines; 2018 Mar; 17(3):257-262. PubMed ID: 29363365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
